Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial
Gilles Montalescot(Maastricht University Medical Centre), Elliott M. Antman(Brigham and Women's Hospital), Eugene Braunwald(Mass General Brigham), C. Michael Gibson(Baim Institute for Clinical Research), Sabina A. Murphy(Brigham and Women's Hospital), Carolyn H. McCabe(Brigham and Women's Hospital), Stephen D. Wiviott(Brigham and Women's Hospital)
Cited by 1,057
Related Papers
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.1k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k